HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)
A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma
Sponsor: Clinigen, Inc.
Terminated
slow accrual led to early closure.
Other terminated trials from Clinigen, Inc.
More terminations from Clinigen, Inc.
Listed as NCT01683188, this PHASE4 trial focuses on Metastatic Melanoma and remains terminated or withdrawn. Sponsored by Clinigen, Inc., it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Mar 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Terminated PHASE4
-
Jul 2019 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinigen, Inc.
- Prometheus Laboratories
For direct contact, visit the study record on ClinicalTrials.gov .